Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Ardelyx stock
Own Ardelyx stock in just a few minutes.
Ardelyx, Inc is a biotechnology business based in the US. Ardelyx shares (ARDX) are listed on the NASDAQ and all prices are listed in US Dollars. Ardelyx employs 129 staff and has a trailing 12-month revenue of around USD$7.6 million.
How to buy shares in Ardelyx
- Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
- Search for Ardelyx. Find the stock by name or ticker symbol: ARDX. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Ardelyx reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Ardelyx, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Ardelyx. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
Ardelyx share price
Use our graph to track the performance of ARDX stocks over time.Ardelyx shares at a glance
Information last updated 2021-04-08.
| 52-week range | USD$4.96 - USD$8.35 |
|---|---|
| 50-day moving average | USD$6.7438 |
| 200-day moving average | USD$6.3532 |
| Wall St. target price | USD$13.86 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | USD$-1.66 |
Buy Ardelyx shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Ardelyx stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Ardelyx financials
| Revenue TTM | USD$7.6 million |
|---|---|
| Gross profit TTM | USD$-57,627,000 |
| Return on assets TTM | -24.6% |
| Return on equity TTM | -60.31% |
| Profit margin | 0% |
| Book value | $1.347 |
| Market capitalisation | USD$751.9 million |
TTM: trailing 12 months
Shorting Ardelyx shares
There are currently 5.7 million Ardelyx shares held short by investors – that's known as Ardelyx's "short interest". This figure is 23.6% up from 4.6 million last month.
There are a few different ways that this level of interest in shorting Ardelyx shares can be evaluated.
Ardelyx's "short interest ratio" (SIR)
Ardelyx's "short interest ratio" (SIR) is the quantity of Ardelyx shares currently shorted divided by the average quantity of Ardelyx shares traded daily (recently around 875859.23664122). Ardelyx's SIR currently stands at 6.55. In other words for every 100,000 Ardelyx shares traded daily on the market, roughly 6550 shares are currently held short.
However Ardelyx's short interest can also be evaluated against the total number of Ardelyx shares, or, against the total number of tradable Ardelyx shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Ardelyx's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Ardelyx shares in existence, roughly 60 shares are currently held short) or 0.07% of the tradable shares (for every 100,000 tradable Ardelyx shares, roughly 70 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Ardelyx.
Find out more about how you can short Ardelyx stock.
Ardelyx share dividends
We're not expecting Ardelyx to pay a dividend over the next 12 months.
Ardelyx share price volatility
Over the last 12 months, Ardelyx's shares have ranged in value from as little as $4.96 up to $8.35. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ardelyx's is 1.947. This would suggest that Ardelyx's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Ardelyx overview
Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of kidney and cardiorenal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program that is in Phase 2 clinical trial for the treatment of patients with hyperkalemia; and RDX020, a small molecule program for the treatment of metabolic acidosis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Fremont, California.
Frequently asked questions
More guides on Finder
-
How to buy Sigma Labs stock
Steps to owning and managing SGLB, with 24-hour and historical pricing before you buy.
-
How to buy Simpson Manufacturing CoInc stock
Steps to owning and managing SSD, with 24-hour and historical pricing before you buy.
-
How to buy Sequans Communications S-A stock
Steps to owning and managing SQNS, with 24-hour and historical pricing before you buy.
-
How to buy SFL Corporation stock
Steps to owning and managing SFL, with 24-hour and historical pricing before you buy.
-
How to buy Senmiao Technology stock
Steps to owning and managing AIHS, with 24-hour and historical pricing before you buy.
-
How to buy Sensata Technologies Holding stock
Steps to owning and managing ST, with 24-hour and historical pricing before you buy.
-
How to buy Select Bancorp stock
Steps to owning and managing SLCT, with 24-hour and historical pricing before you buy.
-
How to buy Second Sight Medical Products stock
Steps to owning and managing EYES, with 24-hour and historical pricing before you buy.
-
How to buy Sibanye Stillwater stock
Steps to owning and managing SBSW, with 24-hour and historical pricing before you buy.
-
How to buy Shinhan Financial Group CoLtd stock
Steps to owning and managing SHG, with 24-hour and historical pricing before you buy.
Ask an Expert